Joseph Fraietta, PhD: Arming CAR T Cells for the Solid Tumor Battlefield

Years Funded: 2020-2022

Metabolic Reprogramming of the CAR T Cell Epigenome
At the University of Pennsylvania Perelman School of Medicine (Philadelphia, PA), Joseph Fraietta, PhD is collaborating with Naomi Haas, MD, to overcome prostate cancer’s stubborn resistance to CAR T-cell therapy. By unlocking the epigenetic code that controls the fate and function of T-cells, this research team expects to improve the success of T -cell therapy in inducing safe, long-term remission for advanced, metastatic prostate cancer.

Read More
Stephen Gottschalk, MD: I Never Need to Ask Myself Why I’m Here

Years Funded: 2020-2022

ECM-Targeted T-Cell Therapy
Building on past research breakthroughs, Stephen Gottschalk, MD, chair of Bone Marrow Transplantation and Cellular Therapy at St. Jude Children’s Research Hospital (Memphis, TN), is moving a new approach to CAR T-cell therapy into clinical trials. Using two different gene protein biomarkers, Dr. Gottschalk expects to fortify a patient’s immune system to successfully attack and destroy sarcomas along with the blood vessels that support their growth.

Read More
Greg Michael Delgoffe, PhD: The Problem with Chemo, Radiation and Surgery

Years Funded: 2017-2019

Metabolic Reprogramming of Tumor-Specific T Cells for Immunotherapy
At the University of Pittsburgh Department of Immunology (Pittsburgh, PA), Greg Michael Delgoffe, PhD, and his team are metabolically reprogramming T cells to make them more robust and fit to fight cancer for longer periods of time.

Read More
Crystal Mackall, MD: Unleashing the Hounds

Years Funded: 2016-2019

GD2 Chimeric Antigen Receptor Therapy for Osteosarcoma
A new iteration of CAR T-cell therapy developed by Crystal Mackall, MD, at Stanford University (Stanford, CA), successfully prepares T cells to seek and destroy solid tumors that express the fatty sugar biomarker GD2. Sensitivity to the GD2 biomarker directs T cells to target solid tumors, such as neuroblastoma, osteosarcoma and diffuse intrinsic pontine glioma (DPIG), in much the same way that T cells are engineered to seek and destroy cancers that express the protein biomarker CD19.

Read More

Join the Alliance

  • This field is for validation purposes and should be left unchanged.